Managing Patients with Obesity-related Complications

Scott Kahan, MD, MPH

Sandra Christensen, MSN, ARNP, FNP-BC, FOMA

OBESITY MANAGEMENT IN PRIMARY CARE CERTIFICATE PROGRAM:

A Practice Management & Leadership Training Program for PAs and NPs

Commercial Support

This activity was sponsored by an educational grant from Novo Nordisk, Inc.

Accreditation Statement

- This activity has been reviewed by **the AAPA Review Panel** and is compliant with AAPA CME criteria. **This activity is designated for 1.5 AAPA Category 1 CME** credits. Participants should only claim credit commensurate with the extent of their participation.
- This activity was planned in accordance with AAPA's CME Standards for Commercial Support of Enduring Activities.
- **This activity is approved for 1.5 contact hour(s) of continuing education by the American Association of Nurse Practitioners**. Activity ID 21075066. This activity was planned in accordance with AANP Accreditation Standards and Policies

House Keeping

Using Your GTW Control Panel and Reminders



Desktop App Control Panel:

(a) Mute/unmute
(b) Raise your hand
(c) Handouts for you to download
(d) Ask (type in) a question



Browser-based Control Panel:

(a) Mute/unmute
(b) Raise your hand
(c) Ask (type in) a question
(d) Handouts for you to download

Questions

- Please post questions throughout the webinar via the **Questions / (?)** section in your GTW control panel (CP)
  - In the Desktop app click on the 'triangle' to open the Questions bar
  - In the browser CP, click on the "?" icon
- Your questions will be addressed during the Q&A section at the end of the webinar

Handouts

- The faculty selected handouts for you to review, use in practice, and/or to follow along with during this session.
  - In the Desktop app CP click on the 'triangle' to open the Handouts bar
  - In the browser CP, click on the "document" icon
- To download the handouts double click on the PDF links

Polling Questions

- There are audience response-like questions that I'll refer to as "polling questions" in this presentation.
- Please be sure to respond to each polling question accordingly. You'll have 10 seconds to submit your responses

POLLING PRACTICE

In what time zone are you located?

A. Eastern (ET)

B. Central (CT)

C. Mountain (MT)

D. Pacific (PT)

E. Island/Alaska Time

AAPA Learning Central: Module 8

Posttest and Evaluation

- After completion of this webinar, please go to Module 8 of the course in AAPA's Learning Central to complete the **posttest** and **evaluation** to obtain credit for this activity.



Please send photo

Faculty and Disclosure Statement

- Scott: please send bio

Vivus: consultant for obesity

Pfizer: consultant for obesity

Gelesis: consultant for obesity

Eli Lilly and Company: consultant for obesity

Please send photo

Faculty and Disclosure Statement

- Sam: please send bio

Novo Nordisk: speakers' bureau for obesity

Gelesis: advisor for obesity

Author royalties: "A Clinician's Guide to Discussing Obesity with Patients"

Objectives

Explain	Explain the pathophysiologic mechanisms by which excess adiposity causes obesity-related complications.
Evaluate	Evaluate obesity-related complications and comorbidities that may require treatment or referral.
Develop	Develop an individualized treatment plan based on a patient's obesity-related complications and comorbidities.
Adjust	Adjust obesogenic medications in a patient's current medication regimen when clinically appropriate.

How do we treat patients with obesity and obesity-related complications?

We treat obesity first!

Complications improve or resolve

In a complications centric approach, the primary endpoint is improvement in adiposity-related complications, not preset decline in body weight.[1]

BMI = body mass index.

Garvey WT, et al. *Endocr Pract*. 2016;22(suppl 3);1-205.

Comorbidities Associated with Obesity



Pulmonary disease
Abnormal function
Obstructive sleep apnea
Hypoventilation syndrome

Fatty liver disease
Steatosis
Steatohepatitis
Cirrhosis

Gall bladder disease

Gynecologic abnormalities
Abnormal menses
Infertility
Polycystic ovarian syndrome
Urinary incontinence

Osteoarthritis

Skin

Idiopathic intracranial hypertension

Stroke

Cataracts

Coronary heart disease
- **Diabetes**
- **Dyslipidemia**
- **Hypertension**

Cancer
Breast, uterus, cervix, colon, esophagus, pancreas, kidney, prostate

Gout

Phlebitis
Venous stasis

Coelho M, et al. *Arch Med Sci*. 2013;9(2):191-200; Schutz DD, et al. *Obes Facts*. 2019;12(1):40-66.

Relationships of Obesity and Comorbidities



Willett WC, et al. *N Engl J Med*. 1999;341:427– 434.

Obesity is Related to 40% of All Cancers in US



Obesity Associated with 236 Discrete Disorders

Color	GRADE	Strength of evidence
	4	Very strong
	3	Strong
	2	Moderate
	1	Weak



Yuen M, Earle R, Kadambi B, Brancale J, Lui D, Kahan S, Kaplan LM. Poster T-P-3166: a systematic review and evaluation of current evidence reveals 195 obesity-associated disorders. Poster presented at: the 34th Annual Scientific Meeting of the Obesity Society; October 31-November 4, 2016; New Orleans, LA. 2016

Impaired Quality of Life



Sturm R. *Health Affairs.* 2002;21(2):245-53.

320,000 Deaths/Year



Grover SA, et al. *Lancet Diab Endocrinol*. 2015;3(2):114-122.
www.milkeninstitute.org/publications/view/833.

How Does Obesity Contribute to Disease?



Heymsfield SB, et al. *NEJM*. 2017; 376(3):254-266.

How Does Obesity Contribute to Disease?

Biomechanical effects

- Arthritis of weight-bearing joints (knees, hips, etc)
- Other musculoskeletal disease (plantar fasciitis, degenerative disc disease)
- Obstructive sleep apnea
- Gastroesophageal reflux disease
- Urinary incontinence
- Others

Psychosocial effects

- Weight stigma
- Internalized weight stigma
- Lower quality of healthcare

Traditional Severity Staging

A Guide to Selecting Treatment					
	BMI category				
Treatment	**25-26.9**	**27-29.9**	**30-34.9**	**35-39.9**	**≥40**
Diet, physical activity, and behavior therapy	With comorbidities	With comorbidities	+	+	+
Pharmacotherapy		With comorbidities	+	+	+
Surgery			With comorbidities		

Increasing benefit? Increasing risk, risk acceptance?

BMI Doesn’t Optimally Predict Body Fat



Gallagher D, et al. *Am J Clin Nutr*. 2000 Sep;72(3):694-701.

BMI Doesn’t Predict Health Outcomes



NHANES = National Health and Examination Survey.

Padwal R, et al. *CMAJ*. 2011;183(14):E1059-E1066.

Severity and Patient Experiences Vary

Absent/Benign	Severe
No impairment of well-being	Severely impaired well-being
No physical symptoms	Severe/debilitating physical symptoms
No functional limitations	Severe/debilitating functional limitations
No adverse metabolic effects	Severe/end-stage metabolic effects
No obesity-related risk factors	Many obesity-related risk factors
No obesity-related comorbidities or medical complications/consequences	Severe obesity-related comorbidities, complications, consequences
No psychological/psychosocial symptoms	Disabling psychological symptoms
No experiences of discrimination, bias	Severe experiences of discrimination
Full QOL	Severely impaired QOL
No lost years of life	Significantly reduced survival

Stratify by Severity/Risk

Obesity and “well”:	Obesity with risk factors:	Obesity and “sick”:
excess weight, but no comorbidities, risk factors, or impaired functioning	excess weight, no overt health consequences, but measurable risk factors for comorbidities/ impairments	excess weight and obesity-attributable comorbidities and impairments

Kahan S, et al. *Curr Obes Rep*. 2013;5(2):291-297.

Proposed Obesity Staging Systems



DIAGNOSIS	ANTHROPOMETRIC COMPONENT	CLINICAL COMPONENT	PREVENTION/ TREATMENT
Normal Weight	BMI < 25 kg/m2		**Primary**
Overweight	BMI ≥ 25 – 29.9 kg/m^2	No obesity-related complications	**Secondary**
Obesity	BMI ≥ 30 kg/m^2	No obesity-related complications	
Obesity Stage 1	BMI ≥ 25 kg/m^2	Presence of one or more mild-to-moderate obesity related complications	**Tertiary**
Obesity Stage 2	BMI ≥ 25 kg/m^2	Presence of one or more severe obesity related complications	

Staging Better Predicts Outcomes

NHANES III (1988-1994)





EOSS = Edmonton Obesity Staging System.

Padwal R, et al. *CMAJ*. 2011;183(14):E1059-E1066.

Staging Impacts Treatment Considerations

Stage 0

- Feels good
- Physically active
- No known risk factors
- No functional limitations
- No mental health issues

Is aggressive treatment worthwhile?
Is any treatment indicated?

Stage 2

- Hypertension
- Diabetes
- Sleep apnea
- Osteoarthritis
- Depression

Consider:
- Intensive counseling or referral
- Pharmacotherapy
- Bariatric surgery

Obesity Treatment Goals



A 5-10% loss can significantly improve health and reduce health risks

Magnitude of Weight Loss for Benefit

Diabetes Prevention	3 - 10%	*Lancet*, 2009; Garvey et al, 2013
Hypertension	5 – (>)15%	Wing, 2011
Dyslipidemia	3 - (>)15%	Wing, 2011
Hemoglobin A1c	3 - (>)15%	Wing, 2011
NAFLD	10%	Assy et al, 2007; Dixon et at, 2004
Sleep Apnea (AHI)	10%	Foster, 2009; Winslow et al, 2012
Osteoarthritis	5-10%	Christensen et al, 2007; Aaboe et al, 2011
Stress Incontinence	5-10%	Burgio et al, 2007; Leslee et al, 2009
GERD	5-10%	Singh et al, 2013; Tutujian R, 2011
PCOS	5-15%	Panidis D et al, 2008; Moran et al, 2013

GERD = gastroesophageal disease; NAFLD = nonalcoholic fatty liver disease; PCOS = polycystic ovarian syndrome.

Iatrogenic Weight Gain

Category	Drugs That May Cause Weight Gain	Possible Alternatives
Neuroleptics	Thioridazine, olanzapine, quetiapine, risperidone	Ziprasidone, aripiprazole
Antidiabetic agents	Insulin, sulfonylureas, thiazolidinediones	GLP1, SGLT2, metformin
Steroid hormones	Contraceptives, glucocorticoids, progestational steroids	Barrier methods, NSAIDs
TCAs	Amitriptyline, nortriptyline, imipramine, doxepin	Protriptyline, bupropion, nefazodone
MAOIs	Phenelzine	Other antidepressants
SSRIs	Paroxetine	Fluoxetine, sertraline
Other antidepressants	Mirtazapine, duloxetine	Bupropion
Anticonvulsants	Valproate, carbamazepine, gabapentin, pregabalin	Topiramate, lamotrigine, zonisamide, felbamate
Antihistamines	Cyproheptadine	Inhalers, decongestants
β- and α-adrenergic blockers	Propranolol, doxazosin	ACEIs, CCBs

ACEI = angiotensin converting enzyme inhibitor; CCB = calcium channel blocker; GLP = glucagon-like peptide; MAOI = monoamine oxidase inhibitor; NSAID = nonsteroidal anti-inflammatory; SGLT = sodium-glucose cotransporter; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.

Apovian CM, et al. *J Clin Endocrinol Metab*. 2015;100:342-362. Kahan S. In: Morton J, et al, eds. *Quality in Obesity Treatment*. 1st ed. Springer International Publishing; 2019.

Case 1: Kalisha

UConn Rudd Center for Food Policy & Obesity

Meet Kalisha

- 32-year-old black female
- Human resources director
- Married with no children

- Here for her annual physical exam with her new primary care nurse practitioner who treats obesity one day per week in her primary care clinic

Weight (lbs)	BMI (kg/m²)	BP (mmHg)	A1c	Fasting Glucose (mg/dL)	Trig (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)	Chol (mg/dL)	AST (IU/L)	ALT (IU/L)
254.9	41.2	118/78	6.1	118	189	51	97	179	46	38

PMH:

G1 P0, miscarriage at 7 weeks, 3 years ago

Current medications

Mirena IUD

- Preventative screening:
  - Last annual and pap 3 years ago
- Family history:
  - Family history of obesity, both parents
  - Mother has T2DM and hypertension
  - Father has hypertension and NAFLD
  - Paternal uncle had stroke at age 61

ALT = alanine aminotransferase. AST = aspartate aminotransferase. BMI = body mass index. BP = blood pressure. Chol = cholesterol. HDL = high-density lipoprotein. IUD = intrauterine device. LDL = low-density lipoprotein. NAFLD = nonalcoholic fatty liver disease. PMH = past medical history. T2DM =type 2 diabetes mellitus.

Kalisha's Additional Concern:

I had a miscarriage 3 years ago after trying to get pregnant for over a year. It was so devastating that I haven't wanted to try again. I'm finally ready, and I want to make sure my body is ready for it.



UConn Rudd Center for Food Policy & Obesity

Kalisha, I'm sorry to hear about your pregnancy loss. Let's review your labs and do the exam so that I can give you a better picture.

Polling Question

How would you classify obesity for kalisha according to the WHO and AACE?

A. Class 2, Stage 0

B. Class 3, Stage 0

C. Class 3, Stage 1

D. Class 3, Stage 2

Assessment



- Class 3, Stage 1 obesity
- Prediabetes
- Hypertriglyceridemia
- Elevated liver enzymes
- Infertility, seeking pregnancy

Polling Question

Which one of Kalisha's diagnoses should be addressed first?

A. Prediabetes

B. Infertility

C. Hypertriglyceridemia

D. Obesity

E. Elevated liver enzymes

Assessment and Plan

- Well woman visit
  - RTC in 1 year
  - Seeking pregnancy; will defer to address obesity first
- Prediabetes
  - Start metformin 500 mg ER once daily x 2 weeks
  - Increase to 500 mg ER BID
  - Begin obesity treatment
- Hypertriglyceridemia
  - Begin obesity treatment
- Elevated liver enzymes
  - Begin obesity treatment
- Infertility with history of pregnancy loss
  - Begin obesity treatment
- Obesity
  - Return for obesity treatment

RTC = return to clinic.

Kalisha's First Obesity-Focused Appointment

	Weight (lbs)	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	254.9	41.2	118/78	87

Medications

- Metformin 500 mg ER once daily X 2 weeks, well tolerated
- Mirena IUD



UConn Rudd Center for Food Policy & Obesity

bpm = beats per minute. P = pulse.

Evaluation

History

Physical

Labs

Pertinent Information from Annual

Medical History

- Prediabetes
- Hypertriglyceridemia
- Elevated liver enzymes
- Infertility, seeking pregnancy

Family History

- Mother and father have obesity and hypertension
- Mother has T2DM
- Father has NAFLD

Physical Exam

- BMI: 41.2 kg/m^2
- WC: 49 inches
- Acanthosis nigricans

Labs

- A1c: 6.1%
- Fasting glucose: 118 mg/dL
- Triglycerides: 189 mg/dL
- AST: 46 IU/L; ALT: 38 IU/L

Kalisha's Weight Graph



Weight History

Nutrition

- First meal at 11 am—breakfast sandwich or pastry
- Late afternoon—hungry, so grabs 1-2 pastries or donuts from the staff room
- Dinner at 7 pm—take out meal or protein, starch, and veggie
- 10 pm—popcorn or candy or ice cream

Physical Activity

- Enjoys exercise, but limited by time
- Walks for an hour with a friend on Saturday morning
- Previously went to a cardio class at the gym, but got out of the habit when work got stressful

Weight History (cont'd)

Sleep / Stress

- Works as an HR director at a large firm
- Long hours– 7:30 am-6:00 pm
- Sleeps midnight to 6 am, sleeps in on weekend

Support System

- Married x 4 years
- Husband has obesity—he will be supportive but will likely tempt patient to indulge with him
- Parents and friends will be moderately supportive

Weight History (cont'd)

Previous Weight Loss Attempts

- Has tried all kinds of diets but can never stick to them
- Most have been low-calorie diets

How Weight Affects Function

- Walking has become more difficult with weight gain
- Feels self-conscious at the gym

Assessment

1. Class 3, Stage 1 obesity
2. Prediabetes
3. Hypertriglyceridemia
4. Elevated liver enzymes
5. Infertility
6. Seeking pregnancy, but deferring for obesity treatment
7. Varied success with past weight loss attempts
8. Disordered eating in afternoon and evenings
9. Weight causing discomfort with physical activity
10. Inadequate sleep

Kalisha's Stepwise Obesity Treatment Plan

- Low-carbohydrate eating plan
- Physical activity routine
- Adequate sleep
- Anti-obesity medications

Plan

Initiate low-carb eating plan

Increase metformin to 500 mg ER BID

RTC in 1 week

One Week Later

	Weight (lbs)	Weight Change (lbs)	Total Weight Change (lbs)	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	254.9	-	-	41.3	118/78	87
1 week	253.7	-1.2	-1.2	41.0	117/74	85

Medications

- Metformin 500 mg ER BID
- Mirena IUD

- Tolerated increased metformin dose well
- Implementing low-carb eating
- Reports less hunger before and after dinner
- Feels more energy and focus at work

Plan

1. Continue current eating schedule
2. Add a 5-10 minute walk 3 days per week
3. Continue 1000 mg metformin daily
4. RTC in 2 weeks

Two Weeks Later

	Weight (lbs)	Weight Change (lbs)	Total Weight Change (lbs)	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	254.9	-	-	41.3	118/78	87
1 week	253.7	-1.2	-1.2	41.0	117/74	85
3 weeks	250.1	-3.6	-4.8	40.2	116/77	85

Medications

- Metformin 500 mg ER BID
- Mirena IUD

- Mostly following low-carb eating plan
- Hunger well-controlled
- Initiated walking routine
- Tolerating metformin

Plan

Continue low-carb eating

Increase weekday walks to 15 minutes on 3-4 days and continue weekend walk

Shift bedtime to 15 minutes earlier (11:45 pm) for one week, then to 11:30 pm the next week

Increase metformin to 1500 mg daily

- RTC in 2 weeks

Two Weeks Later

	Weight (lbs)	Weight Change (lbs)	Total Weight Change (lbs)	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	254.9	-	-	41.3	118/78	87
1 week	253.7	-1.2	-1.2	41.0	117/74	85
3 weeks	250.1	-3.6	-4.8	40.2	116/77	85
5 weeks	247.6	-2.5	-7.3	40.0	119/73	82

Medications

- Metformin 500 mg ER BID
- Mirena IUD

- Following eating plan
- Hunger well-controlled
- Walked for 15 minutes, 3 days per week after lunch and weekend walk; well-tolerated
- Tolerating 1500 mg metformin

Plan

Continue current eating plan

Increase weekday walks to 15 minutes daily

Shift bedtime to 15 minutes earlier once a week until falling asleep at 10:30 (wakes at 6:00 = 7.5 hours sleep)

Increase Metformin to 2000 mg daily

Continue appointments once every 2 weeks

At 3 Months of Treatment

	Weight (lbs)	Total Weight Change (lbs)	% Weight Loss	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	254.9			41.3	118/78	87
3 Months	229.6	-25.3	10.1%	37.1	112/73	81

	A1c	Fast Glu (mg/dL)	Trig (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)	Chol (mg/dL)	AST (IU/L)	ALT (IU/L)
Initial	6.1	118	189	51	97	179	46	38
3 Months	5.7	99	147	55	93	174	32	21

At 3 Months of Treatment

- Mostly following eating plan, but nibbling on carbs in the afternoon some days
- New onset carb cravings that start after lunch and continue until bedtime (open to trying AOM to manage)
- Walks 20-30 minutes daily, with a one hour walk on weekend
- Resumed weekly circuit class at gym
- Sleeps 10:30-6:00 on weeknights; 11:00-7:00 on weekends
- Tolerating 2000 mg metformin ER daily



AOM = anti-obesity medication.

UConn Rudd Center for Food Policy & Obesity

Polling Question

Which anti-obesity medications would you consider to address Kalisha's carbohydrate cravings that begin after lunch?

A. Phentermine-topiramate

B. Naltrexone-bupropion

C. Liraglutide 3.0 mg

D. Semaglutide 2.4 mg

E. Phentermine 15-37.5 mg

F. Phentermine 8 mg (Lomaira)

Plan

- Continue current eating plan
- Increase walks to 45 minutes on weekdays; one hour on weekend
- Continue weekly circuit class
- Continue current sleep schedule
- Continue 2000 mg daily metformin
- Start phentermine 8 mg (Lomaira) one hour prior to lunch
  - If tolerated after 5-7 days, add a second Lomaira mid-afternoon
- RTC in 2 weeks

Two Weeks Later

	Weight (lbs)	Weight Change (lbs)	Total Weight Change (lbs)	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	254.9			41.3	118/78	87
3 Months	229.6	-25.3	10.1%	37.1	112/73	81
3 Mo + 2 Wks	226.3	-28.6	11.2%	36.6	110/71	85

Medications

- Metformin 500 mg ER BID
- Lomaira BID
- Mirena IUD

- Following eating plan
- No carb cravings or consumption since starting Lomaira
- Not sleeping soundly and staying up later since starting Lomaira
- Skipped some walks due to being too tired

Plan

Discontinue Lomaira
Start 1 tablet naltrexone-bupropion once daily in the morning; if tolerated, increase to 1 tablet BID in 1-2 weeks
Continue current eating plan
Resume full physical activity routine
Resume previous sleep schedule
RTC in 2 weeks

Two Weeks Later

	Weight (lbs)	Weight Change (lbs)	Total Weight Change (lbs)	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	254.9			41.3	118/78	87
3 Months	229.6	-25.3	10.1 %	37.1	112/73	81
3 Mo + 2 Wks	226.3	-28.6	11.2%	36.6	110/71	85
3 Mo + 2 Wks	225.1	-29.8	11.7%	36.4	109/73	79

Medications

- Metformin 500 mg ER BID
- Naltrexone-bupropion: 1 tablet BID
- Mirena IUD

- Following eating plan
- No carb cravings or consumption
- Resumed previous physical activity routine
- Resumed previous sleep schedule

Plan

- Continue current eating plan
- Continue current physical activity routine
- Continue current sleep schedule
- Continue metformin
- Titrate naltrexone-bupropion to 2 tablets BID
- Shift appointments to once every 4 weeks
  - RTC sooner if has more than a 3 to 4-pound weight gain or any challenges

At 6 Months of Treatment

	Weight (lbs)	Total Weight Change (lbs)	% Weight Loss	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	254.9			41.3	118/78	87
3 Months	229.6	-25.3	10.1 %	37.1	112/73	81
6 Months	216.3	-38.6	15.1%	35.0	108/72	79

	A1c	Fast Glu (mg/dL)	Trig (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)	Chol (mg/dL)	AST (IU/L)	ALT (IU/L)
Initial	6.1	118	189	51	97	179	46	38
3 Months	5.7	99	147	55	93	174	18	19
6 Months	5.4	92	132	56	96	171	15	18

At 6 Months of Treatment

UConn Rudd Center for Food Policy & Obesity

- Mostly following eating plan
- Carb cravings resolved
- Continues walking / circuit class routine
- On track with sleep schedule
- Continues metformin 2000 mg daily
- Taking naltrexone-bupropion 2 tablets BID
- Feels better physically & emotionally
- Wants to continue active weight loss for another 6 months before having IUD removed
- Husband has lost 15 pounds

At 1 Year

	Weight (lbs)	Total Weight Change (lbs)	% Weight Loss	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	254.9			41.3	118/78	87
3 Months	231.6	-23.3	9.1 %	37.1	112/73	81
6 Months	219.3	-35.6	14.0%	35.0	108/72	79
1 Year	208.4	-46.5	18.2%	33.7	111/75	81

	A1c	Fast Glu (mg/dL)	Trig (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)	Chol (mg/dL)	AST (IU/L)	ALT (IU/L)
Initial	6.1	118	189	51	97	179	46	38
3 Months	5.7	99	147	55	93	174	18	19
6 Months	5.4	92	132	56	96	171	15	18
1 Year	5.3	96	122	57	93	170	16	20

At 1 Year

- Mostly on track with low-carb eating
- Had a few lapses with processed / refined carbs, so increased appointment frequency to every 2 weeks until resolved
- Continues physical activity routine
- Continues sleep routine
- Ready to have IUD removed
- Will continue with monthly appointments

UConn Rudd Center for Food Policy & Obesity

At 3 Years

- Became pregnant 3 months after IUD removed
- Healthy pregnancy with 18-pound weight gain
- Vaginally delivered full-term baby girl
- Successful breastfeeding
- Resumed naltrexone-bupropion after completed breastfeeding
- Continued monthly appointments throughout pregnancy and beyond

At 3 Years

	Weight (lbs)	Total Weight Change (lbs)	% Weight Loss	BMI (kg/m²)	BP (mmHg)	P (bpm)
Initial	254.9	-		41.3	118/78	87
3 Months	231.6	-23.3	9.1 %	37.1	112/73	81
6 Months	219.3	-35.6	14.0%	35.0	108/72	79
1 Year	208.4	-46.5	18.2%	33.7	111/75	81
3 Years	205.3	-49.6	19.5%	33.2	118/76	84

At 3 Years

	A1c	Fast Glu (mg/dL)	Trig (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)	Chol (mg/dL)	AST (IU/L)	ALT (IU/L)
Initial	6.1	118	189	51	97	179	46	38
3 Months	5.7	99	147	55	93	174	18	19
6 Months	5.4	92	132	56	96	171	15	18
1 Year	5.3	96	122	57	93	170	16	20
3 Years	5.4	93	119	56	101	174	17	18

Case 2: Renaldo

© Obesity Action Coalition

Meet Renaldo

- 57-year-old Latino male
- Car mechanic
- Single

- Here to see primary care provider for medication refills
- Last seen 15 months ago for annual

Weight (lbs)	BMI (kg/m²)	BP (mmHg)	A1c	Fasting Glucose (mg/dL)	Trig (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)	Chol (mg/dL)	AST (IU/L)	ALT (IU/L)
320.9	46.1	141/93	8.1	133	211	37	79	161	31	22

PMH:

- T2DM
- Hypertension
- Dyslipidemia
- Depression
- LBP-herniated disc, L4-5

FH:

- Family history of obesity, both parents
- Father had fatal MI at age 64 years
- Father had T2DM and hypertension
- Mother has hypertension and NAFLD

LBP = low-back pain. MI = myocardial infarction.

- Current medications
  - Metformin 2000 mg daily
  - Rosuvastatin 10 mg
  - Lisinopril 20 mg daily
  - Citalopram 40 mg daily
  - Gabapentin 600 mg TID—started two months ago
- Preventative screening:
  - Colonoscopy current

Polling Question

Which of Renaldo's medications are obesogenic?

1. Metformin and lisinopril
2. Rosuvastatin and lisinopril
3. Gabapentin and metformin
4. **Citalopram and gabapentin**
5. Lisinopril and citalopram

Past Medical History

- No diabetes follow-up or labs for 15 months
- Started to get low on medications a few months ago, so decreased doses or only took every 2-3 days
- Developed severe LBP with sciatica three months ago
  - Evaluated by ortho—herniated disc, L4-5
  - Referred to PT, but patient hasn't made an appointment
  - Prescribed gabapentin for pain
- Decreased mobility due to LBP
- Depression worsened with LBP and decreased mobility
- Weight gain since onset of LBP

PT = physical therapy.

Polling Question

How would you classify obesity for Kalisha according to the WHO and AACE?

A. Class 2, stage 0

B. Class 3, stage 0

C. Class 3, stage 1

D. Class 3, stage 2

Assessment

- Class 3, Stage 2 obesity with weight gain of 32.3 pounds in the last 15 months
- Type 2 diabetes, not controlled, with inconsistent follow-up
- Hypertension, not fully controlled with inconsistent medication dosing
- Dyslipidemia, with elevated triglycerides and suppressed HDL
- Depression, worsened
- LBP with herniated disc, L4-5
- Not fully adherent to medications

Assessment and Plan

1. Obesity
   - Begin non-surgical obesity treatment
   - Consider bariatric surgery in the future
2. Diabetes
   - Restart and titrate metformin ER to 2000 mg daily
   - Once tolerating metformin, start semaglutide and titrate to 1.0 mg weekly
   - Begin obesity treatment
3. Hypertension
   - Resume daily lisinopril
   - Begin obesity treatment
4. Dyslipidemia
   - Resume daily rosuvastatin
   - Begin obesity treatment
5. Depression
   - Resume daily citalopram
   - Begin obesity treatment
6. LBP
   - Start PT
   - Begin obesity treatment

Renaldo's First Obesity-Focused Appointment

	Weight (lbs)	BMI (kg/m²)	BP (mmHg)	P (bpm)
Initial	319.3	45.9	132/88	99

Medications

- Taking full doses of all medications

Initial Treatment Strategy

Treat obesity first

Treat diabetes in a manner that optimizes obesity treatment

Use anti-diabetes medications that:

- Don’t cause weight gain
- Promote weight loss

Reduce LBP

- Reduce weight
- Add PT

Plan

Initiate low-carb eating plan

Continue metformin 2000 mg ER BID

Start semaglutide 0.25 mg once weekly

Schedule PT for LBP

Two Weeks Later

	Weight (lbs)	Weight Change (lbs)	Total Weight Change (lbs)	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	319.3			45.9	132/88	99
2 weeks	318.0	-1.3	-1.3	45.7	124/82	85

Medications

- Metformin 2000 mg ER BID
- Semaglutide 0.25 mg weekly
- Lisinopril 20 mg daily
- Rosuvastatin 20 mg daily
- Citalopram 40 mg daily
- Gabapentin 600 mg TID

- Implemented low-carb eating
- Tolerated 0.25 semaglutide
- No reduction in LBP
- Had first PT appointment, will continue twice weekly

Plan

1. Continue low-carb eating
2. Continue current medications
3. Continue PT twice weekly
4. RTC in 2 weeks

Two Weeks Later

	Weight (lbs)	Weight Change (lbs)	Total Weight Change (lbs)	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	319.3			45.9	132/88	99
2 weeks	318.0	-1.3	-1.3	45.7	128/82	85
4 weeks	313.4	-4.6	-5.9	45.0	120/81	88

- Mostly following low-carb eating plan
- Mild appetite reduction
- Continues PT twice weekly
- LBP reduced
- Tolerating semaglutide

Medications

- Metformin 2000 mg ER BID
- Semaglutide 0.25 mg weekly
- Lisinopril 20 mg daily
- Rosuvastatin 20 mg daily
- Citalopram 40 mg daily
- Gabapentin 600 mg TID

Plan

Continue low-carb eating

Continue PT twice weekly

Add a 5-minute daily walk

Increase semaglutide to 0.5 mg weekly

- RTC in 2 weeks

Continue Stepwise Comprehensive Treatment Plan

Nutrition

Continue low-carb eating

Physical activity

Gradually increase as tolerated

Behavior

Encourage adherence to medications and appointments

Pharmacotherapy

- Increase semaglutide to 1.0 mg
- Transition from obesogenic medications to those that are weight neutral or weight negative or discontinue if able
  - Citalopram
  - Gabapentin
- Add AOM

Polling Question

Which anti-obesity medications would you consider for Renaldo?

1. Phentermine-topiramate
2. Naltrexone-bupropion
3. Liraglutide 3.0 mg
4. Semaglutide 2.4 mg
5. Phentermine 15-37.5 mg
6. Phentermine 8 mg (Lomaira)

At 3 Months of Treatment

	Weight (lbs)	Total Weight Change (lbs)	% Weight Loss	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	319.3			45.9	132/88	99
3 Months	294.0	-25.3	7.9%	42.2	116/77	81

Medications

- Metformin 2000 mg ER BID
- Semaglutide 1.0 mg weekly
- Lisinopril 10 mg daily
- Rosuvastatin 20 mg daily
- Bupropion 300 mg XL daily
- Gabapentin 300 mg TID

	A1c	Fast Glu (mg/dL)	Trig (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)	Chol (mg/dL)	AST (IU/L)	ALT (IU/L)
Initial	8.1	133	211	37	79	161	31	22
3 Months	6.9	112	183	34	71	159	32	21

At 3 Months of Treatment

- Fairly adherent to low-carb eating
- Walking 10 minutes daily, exercise bike 3x/wk x 10 minutes
- Taking all medications and attending appointments
- Transitioned from citalopram to bupropion, depression improved
- LBP significantly improved, slowly tapering off gabapentin (50% of previous dose)
- Released from PT; following up with ortho
- Mobility improved

Plan

- Continue current eating plan
- Continue current physical activity with gradual increase in frequency, duration, intensity
- Continue current medications
  - Continue to slowly taper off gabapentin
- Add phentermine-topiramate and titrate as tolerated

At 6 Months of Treatment

	Weight (lbs)	Total Weight Change (lbs)	% Weight Loss	BMI (kg/m^2)	BP (mmHg)	P (bpm)
Initial	319.3			45.9	132/88	99
3 Months	294.0	-25.3	7.9 %	42.2	122/83	81
6 Months	267.9	-51.4	15.1%	38.5	108/72	79

	A1c	Fast Glu (mg/dL)	Trig (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)	Chol (mg/dL)	AST (IU/L)	ALT (IU/L)
Initial	8.1	133	211	37	79	161	31	22
3 Months	6.9	112	183	34	71	159	32	21
6 Months	5.8	104	132	36	70	154	15	18

At 6 Months of Treatment

- Fairly adherent to low-carb eating
- Taking all medications & attending appointments
- Depression stable
- Further improvement in LBP—discontinue gabapentin
- Increased mobility, using exercise bike daily for 15-20 minutes and continues walking 10-15 minutes daily
- Good appetite and craving suppression with phentermine-topiramate

Medications

- Metformin 2000 mg ER BID
- Semaglutide 1.0 mg weekly
- Lisinopril 10 mg daily
- Rosuvastatin 20 mg daily
- Bupropion 300 mg XL daily
- Phentermine-topiramate 11.25/69 mg daily

Plan

- Continue current eating plan
- Continue to gradually increase frequency, duration, intensity of physical activity
- Continue current medications
- RTC monthly

At 1 Year of Treatment

	Weight (lbs)	Total Weight Change (lbs)	% Weight Loss	BMI (kg/m²)	BP (mmHg)	P (bpm)
Initial	319.3			45.9	132/88	99
3 Months	294.0	-25.3	7.9 %	42.2	122/83	81
6 Months	267.9	-51.4	15.1%	38.5	108/72	79
1 Year	263.1	-56.2	17.6%	37.8	115/76	81

At 1 Year of Treatment

	A1c	Fast Glu (mg/dL)	Trig (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)	Chol (mg/dL)	AST (IU/L)	ALT (IU/L)
Initial	8.1	133	211	37	79	161	31	22
3 Months	6.9	112	183	34	71	159	32	21
6 Months	5.8	104	132	36	70	154	15	18
1 Year	6.0	113	154	35	77	161	22	19

At 1 Year of Treatment

Continued to lose weight until two months ago when he stopped taking phentermine-topiramate and regained 8 pounds

Started eating more ultra-processed carbs

LBP worsened with regain

No walking and decreased exercise bike to 15 minutes “a few days a week”

Missed last month’s follow-up appointment due to shame about regaining weight

Ready to refocus, so returned for follow-up

Open to bariatric surgery referral

Medications

- Metformin 2000 mg ER BID
- Semaglutide 1.0 mg weekly
- Lisinopril 10 mg daily
- Rosuvastatin 20 mg daily
- Bupropion 300 mg XL daily
- Phentermine-topiramate 11.25/69 mg daily (but not taking)

Plan

Restart phentermine-topiramate and titrate to previous dose

Resume all previous lifestyle habits

Refer to bariatric surgery

At 3 Years of Treatment

	Weight (lbs)	Total Weight Change (lbs)	% Weight Loss	BMI (kg/m²)	BP (mmHg)	P (bpm)
Initial	319.3			45.9	132/88	99
3 Months	294.0	-25.3	7.9 %	42.2	122/83	81
6 Months	267.9	-51.4	15.1%	38.5	108/72	79
1 Year	263.1	-56.2	17.6%	37.8	115/76	81
3 Years	218.7	-100.6	31.5%	31.4	111/72	76

At 3 Years of Treatment

		A1c	Fast Glu (mg/dL)	Trig (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)	Chol (mg/dL)	AST (IU/L)
Initial	8.1	133	211	37	79	161	31	22
3 Months	6.9	112	183	34	71	159	32	21
6 Months	5.8	104	132	36	70	154	15	18
1 Year	6.0	113	154	35	77	161	22	19
3 Years	5.4	104	115	38	71	155	14	16

3 Years Later

Gastric sleeve 18 months ago

Continues low-carb eating

Exercise and road bike 30-60 minutes daily with strength training 2x/wk

Continues phentermine-topiramate daily

Returns for follow-up every 3 months, with instructions to return sooner if has regain of >5 pounds

Medications

- Metformin 1000 mg ER BID
- Semaglutide 1.0 mg weekly
- Lisinopril 5 mg daily
- Rosuvastatin 5 mg daily
- Bupropion 150 mg XL daily
- Phentermine-topiramate 11.25/69 mg daily

Key Take-away Points

01 Excess adiposity causes obesity-related complications

02 When you treat obesity first, complications improve or resolve

03 Obesity treatment should be implemented in a comprehensive, stepwise manner

04 Utilize treatments that improve both obesity & obesity-related complications

References

Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., Still, C. D., & Endocrine, S. (2015, Feb). Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 100(2), 342-362. https://doi.org/10.1210/jc.2014-3415

Bays HE, McCarthy W, Burridge K, Tondt J, Karjoo S, Christensen S, Ng J, Golden A, Davisson L, Richardson L. Obesity Algorithm eBook, presented by the Obesity Medicine Association. www.obesityalgorithm.org. 2021. https://obesitymedicine.org/obesity-algorithm/

Christensen, S. (2020, Jul). Recognizing obesity as a disease. J Am Assoc Nurse Pract, 32(7), 497-503. https://doi.org/10.1097/JXX.0000000000000482

Eckel, R. H., Bays, H. E., Klein, S., & Bade Horn, D. (2016, Oct). Proactive and Progressive Approaches in Managing Obesity. Postgrad Med, 128 Suppl 1, 21-30. https://doi.org/10.1080/00325481.2016.1181412

Gadde, K. M., Martin, C. K., Berthoud, H. R., & Heymsfield, S. B. (2018, Jan 2). Obesity: Pathophysiology and Management. J Am Coll Cardiol, 71(1), 69-84. https://doi.org/10.1016/j.jacc.2017.11.011

Greenway, F. L. (2015, Aug). Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond), 39(8), 1188-1196. https://doi.org/10.1038/ijo.2015.59

Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., Loria, C. M., Millen, B. E., Nonas, C. A., Pi-Sunyer, F. X., Stevens, J., Stevens, V. J., Wadden, T. A., Wolfe, B. M., Yanovski, S. Z., American College of Cardiology/American Heart Association Task Force on Practice, G., & Obesity, S. (2014, Jul 1). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol, 63(25 Pt B), 2985-3023. https://doi.org/10.1016/j.jacc.2013.11.004

Peterson, K., Anderson, J., Boundy, E., Ferguson, L., & Erickson, K. (2017, Apr). Rapid Evidence Review of Bariatric Surgery in Super Obesity (BMI >/= 50 kg/m(2)). J Gen Intern Med, 32(Suppl 1), 56-64. https://doi.org/10.1007/s11606-016-3950-5

Ryan, D. H., & Kahan, S. (2018, Jan). Guideline Recommendations for Obesity Management. Med Clin North Am, 102(1), 49-63. https://doi.org/10.1016/j.mcna.2017.08.006

Swift, D. L., Johannsen, N. M., Lavie, C. J., Earnest, C. P., & Church, T. S. (2014, Jan-Feb). The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis, 56(4), 441-447. https://doi.org/10.1016/j.pcad.2013.09.012